2310 Alfred-Nobel Boulevard
QC H4S 2B4
Canada - Map
Theratechnologies Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic peptide products with a focus on growth-hormone releasing factor (GRF) peptides. The companys lead product include EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, which is marketed in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. It also develops TH1173, a second-generation GRF peptide that has completed preclinical studies. The company was founded in 1993 and is headquartered in Montréal, Canada.
|Mr. Luc Tanguay M.Sc., C.F.A.,
Chief Exec. Officer, Pres, Non-Independent Director and Member of Financing Committee
|Ms. Marie-No Colussi C.A.,
VP of Fin.
|Mr. Christian Marsolais Ph.D.,
Sr. VP of Scientific Affairs & Alliances
|Mr. Jocelyn Lafond LL.B., L.L.M.,
VP of Legal Affairs and Sec.
|Dr. Krishna Peri Ph.D.,
special counsel to the Pres and Chief Exec. Officer
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|